Sentences with phrase «burkitt lymphoma cell»

«But in many of these cases the implant was removed without testing the surrounding fluid and tissue for lymphoma cells, so it's difficult to definitively correlate the two.»

Several years ago, NCI scientists identified the two primary subtypes of DLBCL based on characteristic patterns of gene activity within the lymphoma cells.

While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches.

Like a free pass, its presence on the surface of lymphoma cells facilitates their migration through the vessel walls between adjacent endothelial cells.

An APC - mimetic scaffold that was engineered to activate a specific type of CAR - T cell was able to generate higher numbers of the modified T cells over longer periods of culture than analogously designed expansion beads, and the resulting cells were similarly effective in killing the lymphoma cells in the mice.

Excitingly, when compared with healthy cells, the lymphoma cells were considerably more sensitive to a reduction in MCL - 1 function.

«We discovered that lymphoma cells with high levels of MYC can be killed by disabling a protein called MCL - 1.

When injected into mice that were then given a subsequent injection of lymphoma cells, the 3D vaccine generated a potent immune response and delayed tumor growth.

Scientists know that the lymphoma cells are dependent on a cytokine called IL - 15 which encourages cells to multiply.

In the laboratory, knocking out PRMT5, or another core component of the splicing machinery in human lymphoma cells lines, also reduced cell viability.

BV is an immunotherapy that targets CD30, a protein on the surface of some Hodgkin lymphoma cells, and delivers a potent dose of chemotherapy to destroy the cell.

Thanks to proceeds from the ride, researchers have identified a subset of non-Hodgkin's lymphoma cells that resist standard chemotherapy and can cause cancer to recur.

GCP, a genistein - rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines.

Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055.

Her mentor was Lindsay Shopland, Ph.D., director of education and the research topic was stimulating proliferation of primary mantel cell lymphoma cells using a combination of MegaCD40L and IL4

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

This discordance may be related to the sample variation between the trephine biopsy and aspirates because of heterogeneous or patchy marrow involvement, a failure to aspirate sufficient lymphoma cells, or insufficient primer homology for amplification.

Mechanistically, decitabine acted synergistically with chidamide to enhance the interaction of KMT2D with transcription factor PU.1, regulated H3K4me - associated signaling pathways, and sensitized T - lymphoma cells to chidamide.

Chip - seq and RNA sequencing data of KMT2D - mutated T - lymphoma cells treated with chidamide and / or decitabine.

Interestingly, we can observe constitutively active RIPK2 in Hodgkin's lymphoma cell lines HDMYZ, L428 (Fig. 4A), and KMH2 cells (Fig. 4B).

Similar results were observed for a third Hodgkin's lymphoma cell line, KMH2 [see (B)-RSB-.

(B) KMH2 Hodgkin's lymphoma cells were inhibited in vivo for 33 — 36 hours using the indicated concentration of RIPK2 inhibitor 1.

(A) Immunoblot illustration of the use of RIPK2 phospho - antibodies in two Hodgkin's lymphoma cells that have constitutive active RIPK2.

Interferon - alpha Resistance in a Cutaneous T - Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression

In one study, vitamin C reduced cancer - causing mutations in mice; in another, it was found to kill up to 50 percent of human lymphoma cells.

The most common site for lymphoma is the lymph nodes, but lymphoma cells, like lymphocytes, can grow anywhere in the body.

In cats, lymphoma cells (like lymphocytes) can grow anywhere in the body, but there are certain sites that are more commonly affected by lymphoma than others (such as the GI tract, mediastinum, and lymph nodes).

Photo: A microscopic view of lymphoma cells in a lymph node.

At this visit, no lymphoma cells were detected.

Stevens says that when he was first diagnosed, a large number of lymphoma cells were collected.

The vet then harvests the stem cells, and the dog is given total body radiation to kill all lymphoma cells.

Dr. Steve Suter on canine lymphoma cell lines.

Not exact matches

This time, the approval is for a type of blood cancer called large B - cell lymphoma.

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.

KTE - C19 spurred either a complete or partial response in 13 out of 19 patients with large B - cell lymphomas.

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

Announced a clinical trial collaboration with Pfizer, Inc. (Pfizer) to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab, a fully humanized 4 - 1BB agonist monoclonal antibody, in patients with refractory large B - cell lymphoma.

Kymriah — the first CAR - T ever to get approval — is now also the first CAR - T to get approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B - cell ALL.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

One of Juno's rivals, Kite Pharma, yesterday said it had completed its enrollment of 72 patients with diffuse large B - cell lymphoma in the Phase II portion of the ZUMA - 1 trial, designed to assess KTE - C19.

Juno is developing its immunotherapy product candidate, JCAR017, which is in a Phase I trial, studying patients with B - cell Non-Hodgkin Lymphoma [NHL].

Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.

«Ultimately, we needed 20 years to learn how to supercharge these cells to deliver anticancer activity,» says Arie Belldegrun, president and CEO of Kite Pharma in Santa Monica, California, which is assessing CAR T cells in six trials for B cell leukemia and lymphomas, and glioblastoma.

These diseases include leukemia or lymphoma, aplastic anemia, severe sickle cell anemia, and severe combined immune deficiency.

Mr. Ostapiuk, 69, of Arlington Heights died of mantle cell lymphoma Tuesday, March 18, in Northwest Community Hospital in Arlington Heights.

Novartis, for example, spent $ 43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.

Dozens of trials are underway, and two CAR - T cell products, for childhood and young adult ALL and aggressive B - cell lymphoma, may be approved later this year by the U.S. Food and Drug Administration (FDA).

However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

The study included Scottish terriers with bladder transitional cell carcinoma, golden retrievers with lymphoma, American cocker spaniels with melanoma, and a fourth group of dogs open to all cancer types.

The most common type of skin lymphoma is caused by the fact that specific immune cells — CD4 - T - lymphocyttes — turn into cancer cells.